
Biogen’s QALSODY® (tofersen) Approved by European Commission for Rare Genetic ALS Treatment
The European Commission (EC) has granted marketing authorization, maintaining orphan designation, for QALSODY® (tofersen) to treat amyotrophic lateral sclerosis (ALS) in adults associated with a mutation in the superoxide dismutase…











